WO2026113269 - NOVEL USE OF 2,4-DISUBSTITUTED-5-FLUOROPYRIMIDINE DERIVATIVE
National phase entry is expected:
Publication Number
WO/2026/113269
Publication Date
04.06.2026
International Application No.
PCT/CN2025/094726
International Filing Date
14.05.2025
Title **
[English]
NOVEL USE OF 2,4-DISUBSTITUTED-5-FLUOROPYRIMIDINE DERIVATIVE
[French]
NOUVELLE UTILISATION D'UN DÉRIVÉ DE 5-FLUOROPYRIMIDINE 2,4-DISUBSTITUÉ
[Chinese]
一种2,4-二取代-5-氟嘧啶衍生物的新用途
Applicants **
KING-EAGLE MED TECHNOLOGY CO., LTD.
Inventors
ZHANG, Hailong
TAN, Yulin
YANG, Wenji
HU, Gaoyun
LI, Youshan
DING, Jingsong
Priority Data
202411745468.3
29.11.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1719 | |
| EPO | Filing, Examination, Granting | 11600 | |
| Japan | Filing, Examination, Granting | 2181 | |
| South Korea | Filing, Examination, Granting | 2107 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,347
Contact Us
Abstract[English]
Provided in the present invention is use of a 2,4-disubstituted-5-fluoropyrimidine derivative or a pharmaceutically acceptable salt thereof in the preparation of drugs for lowering uric acid. The 2,4-disubstituted-5-fluoropyrimidine derivative has the following structural formula (I) and provides a new option for drugs for lowering uric acid.[French]
La présente invention concerne l'utilisation d'un dérivé de 5-fluoropyrimidine 2,4-disubstitué ou d'un sel pharmaceutiquement acceptable de celui-ci dans la préparation de médicaments pour abaisser l'acide urique. Le dérivé de 5-fluoropyrimidine 2,4-disubstitué a la formule structurale suivante (I) et fournit une nouvelle option pour les médicaments pour abaisser l'acide urique.[Chinese]
本发明提供了一种2,4-二取代-5-氟嘧啶衍生物或其药学上可接受的盐在制备降尿酸的药物中的用途，所述2,4-二取代-5-氟嘧啶衍生物具有如下结构式（I），为降尿酸药物提供了新选择。